

Authors' Response to Peer Reviews

# Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

Mark Jarrett<sup>1\*</sup>, MBA, MD; Warren Licht<sup>1\*</sup>, MD; Kevin Bock<sup>1\*</sup>, MHCDS, MD; Zenobia Brown<sup>1\*</sup>, MPH, MD; Jamie Hirsch<sup>1\*</sup>, MA, MSB, MD; Kevin Coppa<sup>2\*</sup>, BSc; Rajdeep Brar<sup>1\*</sup>, MD; Stephen Bello<sup>2\*</sup>, PA, MHCDS; Ira Nash<sup>1\*</sup>, MD

<sup>1</sup>Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, NY, United States

<sup>2</sup>Northwell Health, New Hyde Park, NY, United States

\* all authors contributed equally

**Corresponding Author:**

Mark Jarrett, MBA, MD

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Hofstra University

500 Hofstra University

Hempstead, NY, 11549

United States

Phone: 1 516 463 7516

Email: [mjarrett@northwell.edu](mailto:mjarrett@northwell.edu)

**Related Articles:**

Preprint (medRxiv): <https://www.medrxiv.org/content/10.1101/2021.04.09.21255219v1>

Preprint (JMIR Preprints): <https://preprints.jmir.org/preprint/29638>

Peer-Review Report by Anonymous: <https://med.jmirx.org/2021/3/e33499/>

Published Article: <https://med.jmirx.org/2021/3/e29638/>

(*JMIRx Med* 2021;2(3):e33496) doi: [10.2196/33496](https://doi.org/10.2196/33496)

**KEYWORDS**

infectious disease; monoclonal antibody therapy; COVID-19; experience; therapy; drug; patient outcome; risk; efficacy; approach; treatment; pandemic; antibody; immunotherapy; immune therapy

*This is the authors' response to peer-review reports for “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study.”*

2. Figures changed
3. Added suggested contextualization
4. Fortified Discussion
5. Although we added references and discussion of the inflammatory response to cytokines, it should be recognized that these antibodies work by neutralization of the virus, not by affecting cytokines.

## Round 1 Review [1]

1. Formatting in paper [2] changed as requested

**References**

1. Anonymous. Peer review of "Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study". *JMIRx Med* 2021 Sep;2(3):e33499 [FREE Full text]
2. Jarrett M, Licht W, Bock K, Brown Z, Hirsch J, Coppa K, et al. Early experience with neutralizing monoclonal antibody therapy for COVID-19: retrospective cohort survival analysis and descriptive study. *JMIRx Med* 2021 Sep;2(3):e29638 [FREE Full text]

*Edited by E Meinert; this is a non-peer-reviewed article. Submitted 09.09.21; accepted 09.09.21; published 27.09.21.*

*Please cite as:*

*Jarrett M, Licht W, Bock K, Brown Z, Hirsch J, Coppa K, Brar R, Bello S, Nash I*

*Authors' Response to Peer Reviews of "Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study"*

*JMIRx Med 2021;2(3):e33496*

*URL: <https://med.jmirx.org/2021/3/e33496>*

*doi: [10.2196/33496](https://doi.org/10.2196/33496)*

*PMID: [27629825](https://pubmed.ncbi.nlm.nih.gov/27629825/)*

©Mark Jarrett, Warren Licht, Kevin Bock, Zenobia Brown, Jamie Hirsch, Kevin Coppa, Rajdeep Brar, Stephen Bello, Ira Nash. Originally published in JMIRx Med (<https://med.jmirx.org>), 27.09.2021. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on <https://med.jmirx.org/>, as well as this copyright and license information must be included.